{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Lee VH"],"pubmed_abstract":["<h4>Background</h4>Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and compared to the erlotinib cohort.<h4>Methods</h4>Patients who suffered from metastatic EGFR-mutated NSCLC previously responsive to first-generation TKI and chemotherapy received afatinib until progression, loss of clinical benefits or intolerable toxicity. Treatment response, survival and safety were evaluated and compared to the erlotinib cohort.<h4>Results</h4>Twenty-five and 28 patients received afatinib and erlotinib respectively. More patien"],"journal":["BMC cancer"],"pagination":["147"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4765101"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib."],"pmcid":["PMC4765101"],"pubmed_authors":["Leung DK","Lam KO","Lee VH","Kwong DL","Lam PM","Choy TS","Leung TW"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.","description":"<h4>Background</h4>Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and compared to the erlotinib cohort.<h4>Methods</h4>Patients who suffered from metastatic EGFR-mutated NSCLC previously responsive to first-generation TKI and chemotherapy received afatinib until progression, loss of clinical benefits or intolerable toxicity. Treatment response, survival and safety were evaluated and compared to the erlotinib cohort.<h4>Results</h4>Twenty-five and 28 patients received afatinib and erlotinib respectively. More patien","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2025-04-04T08:10:51.912Z","creation":"2019-03-27T02:09:45Z"},"accession":"S-EPMC4765101","cross_references":{"pubmed":["26911310"],"doi":["10.1186/s12885-016-2201-9"]}}